Topotecan

Mal response was reported for a total die tary concentration of 23% of cottonseed oil Dryden et al., '60; Overby et al., '59b ; . All fats have not been found to be equally effective. Lard Ershoff, '49; Westerfeld and Richert, '52 ; and numerous oils Overby et al., '59b ; afforded good pro tection when added to low fat diets, but the fat extracted from liver residue Over by and Fredrickson, '60b ; was appreciably more active than cottonseed oil, and the activity exhibited by olive oil was greater than could be accounted for by its linoleic acid content Overby et al., '59b ; . Hydrogenated coconut oil was inactive Overby et al., '59b ; . The increased MR following the admin istration of thyroid has been reported to be decreased by the administration of fat Abelin, '26; Abelin and Kursteiner, '28; Abelin et al., '30; Berg, '34 ; or linoleic acid Keeser, '38 ; . Fat feeding has also been reported to restore the loss of liver and muscle glycogen which results from thy roid administration Abelin, '26; Abelin et al., '30; Zain, '36, '37 ; . Casein has been recognized as a poor source of antithyrotoxic activity Tappan et al., '53; Graham et al., '53; Ershoff, '47; Dryden et al., '60; Overby et al., '59a ; , although increasing its dietary concentra tion e.g., from 30 to 40% ; may have a slight protective effect Overby et al., '59c ; .14'15Soybean meal has been reported to vary in activity from poor Tappan et al., '53; Stevens and Henderson, '58 ; to moderate O'Dell et al., '55; Ershoff, '49 ; to good Ershoff, '50 ; . Soy protein has varied similarly Graham et al., '53; Ershoff et al., '59 ; , "-" and different brands of soy protein have given different re sponses in the same laboratory Dryden et al., '60 ; . Lactalbumin and fibrin were reported to have good activity Overby et al., '59c ; , whereas gelatin was inactive.

Even though you may want to move forward in your life, you may have one foot on the breaks. In order to be free, we must learn to let go. Release the hurt. Release the fear. Refuse to entertain your old pain. The energy it takes to hang onto the past is holding you back from a new life. What is it you would let go of today?. Coagulation indices is also necessary in large mass blood replacement.3'5 R. Imberti MD D. Locatelli * MD M. Fanzio MD N. Bonfanti * MD I. Preseglio MD Servizio di Anestesia e Rianimazione II IRCCS Policlinico S. Matteo and * Dipartimento di Chirurgia, Sezione di Neurochirurgia, University of Pavia. FIG. 4. Response of horizontal canal vestibular afferents to rotations with velocities of 500 s. A: response of regular and irregular afferents in normal animals. Data points are shown for one example regular CV * 0.06 ; and irregular CV * 0.4 ; afferent. Sigmoidal functions fit to the data for the example afferents black sigmoid curves ; , as well as the other afferents that were recorded in each condition, are superimposed gray curves ; and provided variance-accounted-for values VAFs ; of 97%. Dashed lines denote the linear portion of the example afferents' responses. B: response of regular and irregular afferents on the contralesional side after unilateral labyrinthectomy. Data points are shown for one example regular CV * 0.05 ; and irregular CV * 0.35 ; afferent. Dashed and gray lines are the same as in A. mean of the sigmoid fit to the responses of the population of irregular and regular afferents before solid lines ; and after lesion dashed lines ; . Gray areas represent the SE of the responses before dark gray ; and after light gray ; lesion. Differences in each group were not significant under the 2 conditions!

The study sample and clinical results have been described previously [13]. In brief, a total of 474 patients with ovarian cancer were enrolled, all of whom had failed or relapsed after first-line chemotherapy with a platinum-based regimen. The study was a randomized phase III trial with sites in Europe 49% from the UK, with eight other sites contributing 10% each ; and North America 93% from the USA ; . Patients were stratified prospectively for platinum sensitivity and bulky disease. Study drug regimens consisted of either a 1-h intravenous infusion of PLD 50 mg m2 every 28 days, or topotecan 1.5 mg m2 day as a 30-min infusion for 5 consecutive days every 21 days. The main clinical outcome measures for efficacy were progression-free survival and overall survival. Patients were followed for 1 year, or until death or disease progression. Weekly topotecan demonstrated antitumor activity and was well tolerated in a patient with recurrent peritoneal papillary serous adenocarcinoma and toradol. SN-38 22 ; . Highly resistant PC-6 SN2-5H cells were further selected from PC-6 SN2-5 cells by continuous exposure to 25 nmol L SN-38 in our laboratory. These cells have no mutation at codon 482 of BCRP 23 ; , which determines the specificity of BCRP substrates 16, 18 ; . MCF-7 human breast cancer cells and mitoxantrone-resistant MCF-7 MX cells were provided by Dr. Masayuki Nakagawa Kagoshima University, Kagoshima, Japan; ref. 24 ; . MCF-7 MX cells have no mutation at codon 482 of BCRP 25 ; . MCF-7 BCRP clone 8 cells, transfectants of the vector pcDNA3-BCRP construct, were kindly provided by Dr. Douglas D. Ross University of Maryland, Baltimore, MD; ref. 17 ; . The transfectants have a mutant form of BCRP R482T; ref. 25 ; . These cells were cultured in RPMI 1640 medium supplemented with 10% FCS Life Technologies, Inc., Grand Island, NY ; and 50 mg L kanamycin sulfate Meiji Seika, Co., Tokyo ; in a humidified incubator containing 5% CO2 at 37jC. Gefitinib was from AstraZeneca, topotecan from SmithKlineBeecham, Co. Tokyo ; , SN-38 from Yakult Honsha, Co. Tokyo ; , mitoxantrone hydrochloride from Takeda Yakuhin Kogyo, Co. Osaka, Japan ; , and doxorubicin from Kyowa Hakko Kogyo, Co. Tokyo ; . Vincristine, etoposide, and novobiocin sodium salt were purchased from Sigma Chemical, Co. St. Louis, MO ; . RNA Extraction and Reverse Transcription-PCR Analysis. Total RNA extraction from culture cells and reverse transcription-PCR were done as previously described 19 ; . The first-strand cDNA was 2-fold diluted from 2.5to 320-fold in reverse transcriptase buffer. Target sequences for the EGFR and glyceraldehyde-3-phosphate dehydrogenase genes were separately.

Ann oncol 1996; 7 suppl 5 ; : 10 bookman ma, malmstrom h, bolis g et al topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase ii study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel and toremifene.

Further investigation of the efficacy of weekly topotecan plus paclitaxel in less heavily pretreated patients is warranted and tracleer.
ADDITIONAL SERVICES 4.11.1 Medicare Part D Premium Subsidy Payment 4.11.1.1 Do you have the capability of administering a subsidy program that assists Medicare-eligible members with the cost of the monthly Part D premium? If you already perform this function for other clients, describe how member data is exchanged with Part D plans and how you determine that the correct plan is paid the correct amount for each member each month. Do you currently have contractual and or working relationships with Medicare Part D plans, including Medicare Advantage plans that offer prescription coverage? If so, describe the nature of these relationships and state whether any of the plans operate in Nevada. Are you licensed as a third-party administrator in Nevada? If not, under what business structure would you perform the function?. Normal, they feel normal, their symptoms are gone, they have a normal physical examination, " he said. "Therefore, it's easy to downplay the significance of what's just happened." Dr. Edlow pointed out that TIA has the same relationship to stroke as deep venous thrombosis does to a pulmonary embolism, or angina does to a myocardial infarction. "Having a patient with TIA gives physicians an opportunity to prevent the stroke by treating the patient after they've had this warning sign but before they've had a fullblown stroke, " he said and trandolapril. ATP-binding cassette transporter A1 ABCA1 ; mediates transport of cellular cholesterol and phospholipids to HDL apolipoproteins, such as apoA-I. ABCA1 mutations can cause a severe HDL deficiency and atherosclerosis. Here we show that the protein tyrosine kinase TK ; Janus kinase 2 JAK2 ; modulates the apolipoprotein interactions with ABCA1 required for removing cellular lipids. The protein kinase A PKA ; inhibitor H89, the TK inhibitor genistein, and the JAK2 inhibitor AG490 suppressed apoA-Imediated cholesterol and phospholipid efflux from ABCA1-expressing cells without altering the membrane ABCA1 content. While PKA inhibition had no effect on apoA-I binding to cells or to ABCA1, TK and JAK2 inhibition greatly reduced these activities. Conversely, PKA but not JAK2 inhibition significantly reduced the intrinsic cholesterol translocase activity of ABCA1. Mutant cells lacking JAK2 had a severely impaired apoA-I-mediated cholesterol and phospholipid efflux and apoA-I binding despite normal ABCA1 protein levels and near normal cholesterol translocase activity. Thus, whereas PKA modulates ABCA1 lipid transport activity, JAK2 appears to selectively modulate apolipoprotein interactions with ABCA1. TK-mediated phosphorylation of ABCA1 was undetectable, implicating the involvement of another JAK2-targeted protein. Acute incubation of ABCA1-expressing cells with apoA-I had no effect of ABCA1 phosphorylation but stimulated JAK2 autophosphorylation. These results suggest that the interaction of apolipoproteins with ABCA1-expressing cells activates JAK2, which in turn activates a process that enhances apolipoprotein interactions with ABCA1 and lipid removal from cells.

1 Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47. Cornelison TL, Trimble EL, Kosary CL. SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988-1994. Gynecol Oncol 1999; 74: 350-355. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita Jr. VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Sixth Edition. Philadelphia: Lippincott Williams & Wilkins, 2001: 2: 1597-1632. Ozols RF. Update of the NCCN ovarian cancer practice guidelines. Oncology Huntingt ; 1997; 11: 95-105. Kavanagh JJ, Kudelka AP, de Leon CG et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996; 2: 837-842. Rose PG, Blessing JA, Mayer AR et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405-410. Lund B, Hansen OP, Theilade K et al. Phase II study of gemcitabine 2, 2-difluorodeoxycytidine ; in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-1533. Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 2002; 29: 9-10. Maurel J, Zorrilla M, Puertolas T et al. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 2001; 12: 713-717. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322. Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14: 3056-3061. Kudelka AP, Tresukosol D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552-1557. Swisher EM, Mutch DG, Rader JS et al. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997; 66: 480-486. Bookman MA, Malmstrm H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label. Sexually dimorphic gene expression in somatic tissues. Jrg Isensee, MSc Patricia Ruiz Noppinger, PhD The sexually dimorphic differentiation of the bipotential gonad into testis or ovary initiates the sexually dimorphic development of mammals and leads to divergent hormone levels between sexes for the entire life time. However, despite the fact that anatomical and hormonal differences between genders are well described, only a few studies investigated the manifestation of these differences at the transcriptional level in somatic tissues. More recently, the application of microarray technology enabled the systematic evaluation of sex-biased gene expression on transcriptome level indicating that the regulatory pathways underlying sexual differentiation are giving rise to extensive differences in gene expression in adults. A sustainable annotation of sex-biased gene expression represents a key towards the understanding of basic physiological differences between males and females in the healthy as well as diseased condition. This review focuses on basic regulatory mechanisms of sex-specific gene expression and discusses recent gene expression profiling studies to outline basic differences between sexes on transcriptome level in somatic tissues and triazolam and topotecan. Camptothecin CPT ; analogues and derivatives serve as a novel class of effective anticancer agents that exert their action against DNA topoisomerase I. This paper presents procedures for the rapid, high frequency regeneration of a camptothecin producing plant, Ophiorrhiza prostrata D. Don from leaf and internode explants via shoot organogenesis. The concentrations of plant growth regulators and explant types exhibited discrete roles in the efficacy of shoot induction. N6benzyladenine BA ; was the most effective cytokinin for the induction of shoots. Murashige and Skoog MS ; medium with 8.87 M BA and 2.46 M indole-3-butyric acid IBA ; yielded the highest number of shoots from leaf and internode explants 76.0 and 90.8 shoots respectively ; . In the case of leaf explants, explants from the proximal end produced a higher number of shoots than those from the mid and distal end. Leaf and internode explants cultured on MS medium supplemented with -naphthaleneacetic acid NAA ; and BA developed shoots, calli and roots. Calli subcultured onto medium supplemented with 8.87 M BA and 2.46 M IBA developed a mean of 20.1 shoots within 40 days. Excision and culture of internode and proximal leaf explants from the established cultures on MS basal medium significantly enhanced the number of shoots and yielded a mean of 18.3 and 13.7 shoots respectively within 40 days. Histological examination of leaf explants showed that the shoots were of sub-epidermal origin, confined to the sub-epidermal cells above the vascular traces. Shoots cultured on half-strength MS basal medium with 10.74 M NAA and 2.32 M Kn produced a mean of 48.2 roots per shoot. Direct transfer of rootless healthy shoots showed a 50% survival rate, whilst it was 100 percent in the case of in vitro rooted shoots. Camptothecin CPT ; , isolated and characterized for the first time by Wall et al. 1966 ; , is a monoterpene indole alkaloid originally derived from Camptotheca acuminata Nyssaceae ; , a native of North China. Members of the Icacinaceae, Olacaceae, Rubiaceae, and Apocynaceae families are also reported to produce camptothecin. CPT analogues and derivatives are a novel class of effective anticancer agents that exert their action against DNA topoisomerase topo ; I Redinbo et al. 1998 ; . The worldwide market size of camptothecin derivatives e.g. topotecan and irinotecan ; reached 1.5 billion US dollars in 2002 Lorence and Nessler, 2004 ; . Due to the cytotoxicity.

Mice bearing OVCAR-3 ascites were treated after 10 days with topotecan 0.625 mg kg day 5 days a week for three consecutive weeks. Pathological response was assessed by morphological study of formalin-fixed, paraffinembedded tissue. Histological diagnosis was based on sections 5-lm thick ; from each block stained with hemalun-eosin. The peritoneal cavity wash was microscopically examined for liver and diaphragmatic metastases and tumour cells every 7 days until death and trifluoperazine.
This list is not an exhaustive list and is intended to give examples of some of the most common brand names of otc drugs. Nerve and muscle membranes and to increase the miniature end-plate potentials' frequency. To investigate its mode of action at the membrane level, we have studied the toxin's effects on the frog myelinated nerve fibre. We show that SNTX creates large cation-selective channels that open and close spontaneously. The conductance of these channels, almost constant in the voltage range -100 to + 50 mV, is 760 pS. The SNTX-induced channels are almost equally permeable to Na + , and Cs', but are impermeable to Ca + The open and closed times of SNTX-induced channels are voltage dependent, the open probability increasing with increased negative membrane potentials. To our knowledge, this is the first demonstration of the production of single-channel currents by a toxin, in a biological membrane.

More results links pop open rate hide advertisements find an ad advertise your site 9 ; hycamtin topotecan ; - drug information from medilexicon medical news today.

Sera from mev mice from three of three mice ; also reacted with the 110-kDa band present in skin extract from wild-type but not from Dsg3-deficient mice. This band was not detected by sera from fsn, scurfy, or wild-type C57BL 6 mice Fig. 1 Right and data not shown.

Topotecan was discontinued, and the patient was discharged with home oxygen and toradol. Appropriate management of high serum cholesterol can lead to a decreased risk of developing coronary heart disease. Treatment guidelines uniformly recommend addressing LDL-C as a first step. Clinical trials support these guidelines, with a lower rate of cardiovascular events and reduction in the progression of atherosclerosis or regression of atherosclerosis in trials incorporating HDL-C-raising and TG-lowering strategies in addition to LDL-C lowering. Fig 6. Morphologic features of topotecan-treated ALL cells undergoing apoptosis. After treatment with 50 nmollL topotecan for 24 hours, NALM-6 cells were examined on WrightGiemsa-stained cytospin slides for morphologic changes characteristicof apoptosis, including nuclear chromatin condensation, segmentationofthe nucleus, and plasma membrane blebs. Apoptotic cells are indicated with arrows.

Quality and safety the storage facilities were generally adequate in most state warehouses while this was not the case in health facilities. ONSET OF MELT ON THE GREENLAND ICE SHEET P. Calanca 1 ; and K. Steffen 2 ; 1 ; Climate Research, Swiss Federal Institute of Technology 2 ; CIRES, University of Colorado In central west Greenland, at the altitude of the equilibrium line, the melting season usually starts at the end of May. Meteorological observations and measurements of the surface energy budget carried out in 1995 show that the onset of melt is triggered by a major warming event that follows from the rearrangement of the large-scale circulation. The rapidity of the onset and the persistence of melt, on the other hand, are controled by the refreezing of percolating water and the albedo feedback. The observational evidence point to the importance of sublimation evaporation for limiting the overall losses through melt. Although sublimation evaporation is small in terms of mass, it is comparable to melt in terms of energy. It is not yet clear what embolotherapy may have to offer in controlling the symptoms from adenomyosis. There were three recent reports of experience with embolization in patients with adenomyosis. Two small studies demonstrated that in patients with fibroids and adenomyosis, embolization had similar rates of symptomatic improvement. In a small group N 13 ; at Georgetown, 92% had symptomatic improvement in both menorrhagia and pelvic pain and pressure. In this series, there was reduction in the fibroid volume and uterine volume. There was not a significant change in the internal appearance of the adenomyosis, although in some cases there was regression of the adenomyosis extent 6 ; . At Albany Medical School, Siskin treated 14 patients with focal adenomyomas or diffuse adenomyosis 7 ; . In 90% of the patients, there was improvement in symptoms. Regression in uterine volume, focal adenomyoma volume, and thickness of the junctional zone was noted in all cases, Ahn and his associates from Korea presented a much larger series N 65 ; at the SCVIR 2000 8 ; . Twenty-nine percent of the group had both myomas and adenomyomas, with the balance having adenomyosis alone. Among all patients, 93.8% reported improvement in symptoms. The authors used varying sizes of polyvinyl alcohol particles, and commented that coagulation necrosis only occurred when particles of 355-500 micron size or smaller. They suggested that this finding is necessary to assure clinical improvement. The group at Georgetown used 500-710 micron size particles and did not see infarction of the adenomyosis, but had similar rates of symptomatic improvement. Certainly additional study is needed to determine the role that UAE will play in the treatment of adenomyosis, but these initial reports are very encouraging. The optimal method for embolization has yet to be determined and validated outcome measures have yet to be used in assessing embolotherapy.

Ineligible at study entry no bidimensional measurable lesion in progression since last evaluation ; . Patients' and diseases' characteristics at inclusion are summarized in Table 1. The median time from initial diagnosis to the first irinotecan infusion was 20.3 months. The majority of patients 66% ; presented with metastatic disease at study entry; 29% of patients were treated at the second relapse, and 14% had a refractory tumor. All patients had received prior chemotherapy, 60% underwent surgery and 74% had radiotherapy. Most of the patients were treated at diagnosis by the Malignant Mesenchymal Tumors protocols 84 and 89 from the Societe Internationale d'Oncologie Pe diatrique SIOP ; protocols that included courses of ifosfamide, dactinomycin, and vincristin IVA ; , and or carboplatin, epiadriamycin, and vincristin CEV ; , and or ifosfamide, vincristine, and etoposide IVE ; . Only one patient received a topoisomerase I inhibitor topotecan ; before study entry. Only one patient received enzyme-inducing anticonvulsant drug during the first cycle of treatment with irinotecan. Efficacy Results In the FAP n 35 ; , the ORR to irinotecan was 11.4% 95% CI, 3.2% to 26.7% ; with one CR 2.9% ; and three PRs 8.5%; Table 2 ; . The response durations were 7.8 months for the CR, 2.8, 3.7, and 6.4 months for the three PRs. Stable disease was observed in 17% of patients. The patient with CR had a stage IV alveolar RMS of the anterior chest wall and patients with PRs had stage IV alveolar n 1 ; or embryonal n 2 ; RMS. One additional patient experienced a PR after two cycles that was not confirmed on the computed tomography scan performed 8 weeks apart. In the per-protocol population n 32 ; , the ORR was 12.5% 95% CI, 3.5% to 29.0% ; with one CR 3.1% ; and three PRs 9.4% ; . In the FAP, the median TTP was 1.4 months 95% CI, 1.2 to 1.6 months ; and the median survival time was 5.8 months 95% CI, 4.3 to 9.4 months ; . Treatment Exposure Overall, 112 cycles were administered to 35 patients, with a median number of two cycles per patient range, 1 to 16 cycles ; . The median dose intensity 195.4 mg m2 wk ; corresponded to 98% of the scheduled dose. The dose was reduced in 14% of patients and 5% of cycles, mainly due to hematologic toxicity. Treatment was delayed in 14% of patients and 14% of cycles, mainly due to reasons other than toxicity. The reasons for treatment discontinuation were progressive disease n 26 ; , no further benefit expected n 3 ; , death due to malignant disease n 2 ; , occurrence of an adverse event related to irinotecan n 1 ; , patient who required radiotherapy n 1 ; , consent withdrawn n 1 ; , and investigator's decision n 1 ; . Safety Results As expected, myelosuppression and gastrointestinal disorders were the main toxicities resulting from treatment Tables 3 and 4 ; . Grade 3 anemia occurred in 11% of patients and 6% of cycles. Grade 3 4 neutropenia occurred in 46% of patients and 49% of cycles. The median time to nadir for grade 3 4 neutropenia was 9 days range, 6 to 20 days ; and the median time to recover from grade 3 or 4 least a grade 2 was 4 days range, 2 to 13 days ; . Six patients 17% ; had grade 4 neutropenia lasting more than 7 days 6% of cycles ; . No patient received granulocyte colony-stimulating factor or granulocytemacrophage colony-stimulating factor. Only three patients 9% ; experienced febrile neutropenia. Grade 3 thrombocytopenia was not complicated by hemorrhage or hospitalization for platelet transfusion. Abnormalities of hepatic or renal enzymes were generally mild to moderate and reversible.
On more than one occasion, Carl has spotted problems in the catenary system that required stopping train movement in a timely and safe manner. In one instance, his actions possibly prevented pantograph damage and , 000 in repair costs. "If there is a situation where someone is needed to troubleshoot, and we hear that Carl Lewis is going to check it out, our comfort level increases and we all breathe easier, " said Tim Gola, tower director. Working in the high-voltage environment of Electric Traction, Carl knows and respects the dangers of the job, and consistently conducts thorough job safety briefings. Managers and peers alike agree that he is one of the most safety-conscious individuals in Amtrak. Carl S. Lewis Jr. sets a standard that others would do well to emulate.